IJCEP Copyright © 2007-All rights reserved.
Int J Clin Exp Pathol 2013;6(1):31-40

Original Article
A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1

Rikke H Dahlrot, Bjarne W Kristensen, Jacob Hjelmborg, Jørn Herrstedt, Steinbjørn Hansen

Department of Oncology, Odense University Hospital, Odense, Denmark; Department of Pathology, Odense University Hospital, Odense,
Denmark;  Institute of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Biostatistics, Institute of Public
Health, University of Southern Denmark, Odense, Denmark

Received October 28, 2012; Accepted November 10, 2012; Epub November 20, 2012; Published January 1, 2013

Abstract: High-grade gliomas have a dismal prognosis, and prognostic factors are needed to optimize treatment algorithms. In this study we
identified clinical prognostic factors as well as the prognostic value of isocitrate dehydrogenase 1 (IDH1) status in a population-based group of
patients with high-grade gliomas. Using the Danish Cancer Registry and the Danish Pathology Databank we identified 359 patients: 234 had
WHO grade IV gliomas, 58 had WHO grade III gliomas, and 67 were diagnosed clinically. Mutated IDH1 was predominantly observed in
oligodendroglial tumors (WHO grade III). Patients with mutated IDH1 had a significantly better outcome than patients with wildtype IDH1: 2-year
OS 59% and 18%, respectively (HR 0.38, 95% CI 0.21-0.68). However, when adjusting for other prognostic factors, IDH1 status was not a
significant independent prognostic factor (HR=0.58, 95% CI 0.32- 1.07). Young age, absence of neurological deficit, performance status 0–1,
tumor not crossing the midline, and receiving post-surgical treatment were significant independent indicators of a good prognosis in
multivariate analysis. In conclusion: This population-based study could not demonstrate IDH1 status to be an independent prognostic factor in
high-grade gliomas when adjusting for the effect of classic prognostic factors. (IJCP1210018).

Keywords: Glioblastoma, high-grade gliomas, prognosis, population characteristics, isocitrate dehydrogenase 1 (IDH1)

Address all correspondence to:
Dr. Rikke H Dahlrot
Department of Oncology
Odense University Hospital
E-mail: Rikke.dahlrot@ouh.regionsyddanmark.dk;
Or: Dr. Steinbjørn Hansen, The Department
of Oncology, Odense University Hospital.
E-mail: Steinbjoern.hansen@ouh.regionsyddanmark.dk